GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Diamyd Medical AB (FRA:DMN) » Definitions » LT-Debt-to-Total-Asset

Diamyd Medical AB (FRA:DMN) LT-Debt-to-Total-Asset : 0.00 (As of Nov. 2024)


View and export this data going back to 2018. Start your Free Trial

What is Diamyd Medical AB LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Diamyd Medical AB's long-term debt to total assests ratio for the quarter that ended in Nov. 2024 was 0.00.

Diamyd Medical AB's long-term debt to total assets ratio stayed the same from Nov. 2023 (0.00) to Nov. 2024 (0.00).

Diamyd Medical AB LT-Debt-to-Total-Asset Historical Data

The historical data trend for Diamyd Medical AB's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Diamyd Medical AB LT-Debt-to-Total-Asset Chart

Diamyd Medical AB Annual Data
Trend Aug15 Aug16 Aug17 Aug18 Aug19 Aug20 Aug21 Aug22 Aug23 Aug24
LT-Debt-to-Total-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - 0.08 0.14

Diamyd Medical AB Quarterly Data
Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24
LT-Debt-to-Total-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - 0.14 -

Diamyd Medical AB LT-Debt-to-Total-Asset Calculation

Diamyd Medical AB's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Aug. 2024 is calculated as

LT Debt to Total Assets (A: Aug. 2024 )=Long-Term Debt & Capital Lease Obligation (A: Aug. 2024 )/Total Assets (A: Aug. 2024 )
=2.677/18.946
=0.14

Diamyd Medical AB's Long-Term Debt to Total Asset Ratio for the quarter that ended in Nov. 2024 is calculated as

LT Debt to Total Assets (Q: Nov. 2024 )=Long-Term Debt & Capital Lease Obligation (Q: Nov. 2024 )/Total Assets (Q: Nov. 2024 )
=0/19.246
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Diamyd Medical AB  (FRA:DMN) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Diamyd Medical AB LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Diamyd Medical AB's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Diamyd Medical AB Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Diamyd Medical AB (FRA:DMN) » Definitions » LT-Debt-to-Total-Asset
Comparable Companies
OSTO:SYNACT XSAT:HAMLET B OSTO:SANION OSTO:MAGLE OSTO:XSPRAY OSTO:FLUO OSTO:IBT B OSTO:GENO OSTO:IRLAB A OSTO:EGTX VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC XKRX:068270 BNTX
Traded in Other Exchanges
DMYD B:Sweden
Address
Kungsgatan 29, Stockholm, SWE, SE-111 56
Website
https://www.diamyd.com
Diamyd Medical AB is a Sweden-based company engaged in the field of pharmaceutical development. It develops therapies using in-licensed substances glutamic acid decarboxylase (GAD) and GABA for the prevention or treatment of diabetes and other inflammatory diseases. The firm is focused on finding the cure for diabetes and other serious inflammatory diseases through pharmaceutical development and investments in stem cells and medical technology. Its product portfolio consists of Diamyd, for the treatment of autoimmune diabetes; Remygen, a regenerative and immunomodulatory therapy for the treatment of autoimmune diabetes and type 2 and type 1 diabetes.